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Abstract
APOBEC3G (A3G)/APOBEC3F (A3F) are two members of APOBEC3 cytidine deaminase subfamily. Although they potently
inhibit the replication of vif-deficient HIV-1, this mechanism is still poorly understood. Initially, A3G/A3F were thought to
catalyze C-to-U transitions on the minus-strand viral cDNAs during reverse transcription to disrupt the viral life cycle.
Recently, it was found more likely that A3G/A3F directly interrupts viral reverse transcription or integration. In addition, A3G/
A3F are both found in the high-molecular-mass complex in immortalized cell lines, where they interact with a number of
different cellular proteins. However, there has been no evidence to prove that these interactions are required for A3G/A3F
function. Here, we studied A3G/A3F-restricted HIV-1 replication in six different human T cell lines by infecting them with
wild-type or vif-deficient HIV-1. Interestingly, in a CEM-derived cell line CEM-T4, which expresses high levels of A3G/A3F
proteins, the vif-deficient virus replicated as equally well as the wild-type virus, suggesting that these endogenous
antiretroviral genes lost anti-HIV activities. It was confirmed that these A3G/A3F genes do not contain any mutation and are
functionally normal. Consistently, overexpression of exogenous A3G/A3F in CEM-T4 cells still failed to restore their anti-HIV
activities. However, this activity could be restored if CEM-T4 cells were fused to 293T cells to form heterokaryons. These
results demonstrate that CEM-T4 cells lack a cellular cofactor, which is critical for A3G/A3F anti-HIV activity. We propose that
a further study of this novel factor will provide another strategy for a complete understanding of the A3G/A3F antiretroviral
mechanism.
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Introduction
Cytidine deaminases are RNA-editing enzymes that target
cytosines for conversion to uracils (C-to-U). They belong to the
apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like
(APOBEC) family, which includes activation-induced deaminase
(AID), APOBEC1 (A1), APOBEC2 (A2), a group of APOBEC3
(A3), and APOBEC4 (A4) in humans [1]. A1 is the original
member of this family and remains the best characterized. It has
the capability to introduce a premature termination codon on
apolipoprotein B100 (apoB) mRNA by C-to-U editing to produce
a truncated form of this protein [2]. AID is the second member
identified. It edits specific ‘‘hotspots’’ on immunoglobulin gene loci
in activated B cells to direct somatic hypermutation and isotype
class switching to generate different antibodies [3].
The human A3 subgroup contains seven members: A3A, A3B,
A3C, A3DE, A3F, A3G, and A3H. All these proteins have
antiretroviral activities against different targets, including exoge-
nous retroviruses and endogenous retroelements [1]. The
replication of human immunodeficiency virus type 1 (HIV-1) is
inhibited by A3B, A3DE, A3F, A3G, and A3H [4–11], and A3G
shows the most powerful anti-HIV-1 activity [9]. A3G/A3F also
blocks various retroelements, including LTR retrotransposons and
non-LTR retrotransposons [12–18]. Nevertheless, HIV-1 is able
to elude this defense mechanism and cause disease in humans for
two reasons. First, A3B and A3H are poorly expressed in vivo
[5,7,19,20]. Second, HIV-1 produces a viral infectivity factor (Vif)
that binds to and mediates the destruction of A3DE, A3F, and
A3G in 26S proteasomes via recruitment of the Cullin5 ubiquitin
E3 ligase [6,10,11,21–25]. Recently, a protein degradation–
independent mechanism was also reported [26].
The antiretroviral mechanism of these A3 proteins has been
extensively studied. Initially, it was found that A3G proteins
deaminate deoxycytidines (dCs) to form deoxyuridines (dUs) on
viral minus-strand cDNAs during viral reverse transcription [27–
30]. These C-to-U mutations could either cause the degradation of
the viral minus-strand cDNAs or result in G-to-A hypermutations
in the plus-strand viral cDNAs, which create havoc in viral
transcripts and produce noninfectious virions. Although this model
has been favored for a while, recent investigations suggest that the
cytidine deamination may not be absolutely required for A3
antiretroviral activity. First, it was found that anti-HIV activity of
A3G/A3F does not correlate with hypermutations, but correlates
with the reduction of viral reverse transcripts [31]. In addition,
A3F and A3H were shown to inhibit HIV-1 replication in the
absence of hypermutations [5,32]. Second, A3G/A3F and other A3
proteins were also shown to inhibit the replication of some other
retroviruses or retrotransposons in the absence of hypermutation
[14,15,18,33–37]. Further investigations demonstrated that A3G/
A3F could interrupt viral reverse transcription by reducing the
efficiency of tRNA
lys3 priming to the viral RNA template,
elongation, and DNA strand transfer [38–43]. Moreover, they could
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enzymatic reactions are inhibited by A3G/A3F is still not clear.
To understand the mechanism of A3G/A3F antiretroviral
activity, efforts have made in another direction by isolating their
cellular binding proteins, although there is no evidence to prove
that they are functionally required. Both A3G and A3F were
found in a ,700 kDa high-molecular-mass (HMM) complex in
immortalized cell lines [45,46]. Unlike A3F, the A3G HMM
complexes are RNase-sensitive; when treated with RNase A, they
fall apart into 100 kDa low-molecular-mass (LMM) complexes.
Biochemical isolations of A3G/A3F-binding proteins from these
HMM complexes have generated a list that contains almost 100
different proteins, some of which are shared by A3G and A3F [47–
50]. However, it is still unclear whether these interactions are
essential for A3G/A3F antiviral activities.
In this report, we studied the anti-HIV-1 activity of A3G/A3F
in six different human T cell lines. We found that A3G/A3F lost
anti–HIV-1 activity in the CEM-derived cell line CEM-T4.
Further investigation demonstrated that CEM-T4 cells lacked a
cellular cofactor. These results lead to a new direction of
investigation on the mechanism of how A3G/A3F inhibits
retroviral replication.
Results
Identification of an A3G/A3F-Expressing Human T Cell
Line Permissive for the HIV-1DVif virus
To study A3 protein antiretroviral activity, six human T cell
lines, including HUT 78, HUT 78–derived H9 and PM1, and
CEM-derived CEM-SS, CEM-T4, and A3.01, were selected for
HIV-1 infection. HUT 78 and H9 cells are nonpermissive cells
because they express A3G and restrict HIV-1DVif virus replica-
tion; A3.01 cells are semipermissive cells because the HIV-1DVif
virus is not completely restricted although it expresses A3G; and
CEM-SS cells are permissive cells because they do not express
A3G and no longer restrict HIV-1DVif replication [51]. CEM-T4
is a natural subclone of CEM and isolated by its relatively high
CD4 expression (Paul Clapham, personal communication). The
permissiveness of PM1 and CEM-T4 for the HIV-1DVif virus has
not been determined. To understand whether there is a significant
difference in CD4 levels in these cells, the surface expression of
CD4 and CXCR4 was determined by flow cytometry. No
significant difference in CD4 and CXCR4 expression was
observed, although CEM-T4 cells did show a slight high CD4
expression (Figure 1A).
Next, these cells were infected with wild-type or vif-defective
HIV-1, and viral replication curves were determined for 8 d.
Although a robust replication of the wild-type virus was observed
in all six cell lines, a significant variation in vif-defective virus
replication was found (Figure 1B). The replication of HIV-1DVif
was completely restricted in HUT 78, H9, and PM1 cells; less
severely restricted in A3.01 cells; and not restricted at all in CEM-
SS and CEM-T4 cells. This result indicated that CEM-T4 should
belong to the permissive cell type with no A3G/A3F expression.
To confirm this, A3G and A3F expressions were determined by
Western blotting. High levels of A3G were detected in CEM,
A3.01, H9, HUT 78, and PM1 cells, and no A3G expression was
detected in CEM-SS cells (Figure 1C), which is consistent with
previous observations. Strikingly, a high-level of A3G expression
was also detected in CEM-T4 cells. In addition, A3F expression
was also detected in CEMT4 as well as H9, A3.01, and HUT 78
cells, but not in CEM-SS cells (Figure 1C). These unexpected
results caused us to conclude that although CEM-T4 cells express
A3G/A3F, they are unable to block HIV-1 replication.
Characterization of A3G from CEM-T4 Cells
Because A3G has much more potent anti–HIV-1 activity than
A3F, we decided to further characterize the A3G protein from
CEM-T4 cells to understand why A3G could not inhibit HIV-1
replication. First, we cloned and sequenced the A3G gene. No
mutation was found in this gene from this cell line (unpublished
data). Second, we determined whether a defect at a post-
translational level was present that could disrupt A3G interaction
with other cellular partners. The A3G protein complex was
isolated from CEM-T4 cells by sedimentation of cell lysates in
sucrose gradients as described previously [46]. A3G was found in
the HMM complexes in CEM-T4 cells as it was in 293T and
A3.01 cells and, importantly, they were sensitive to conversion to
LMM complexes upon RNase A treatment (Figure 2A). This result
indicated an intact ability of A3G to interact with cellular RNAs
and proteins. Third, we determined A3G cytidine deaminase
activity by a scintillation proximity-based assay using an A3G-
specific template. As presented in Figure 2B, cells such as 293T
and CEM-SS that do not express A3G had marginal deaminase
activity; CEM-T4 and A3.01 cells that express A3G had higher
levels of activity, which were significantly increased after RNase A
treatment. These results confirmed that A3G is present in HMM
complexes in these cells (Figure 2A) and further indicated that
A3G in CEM-T4 cells is enzymatically active. Thus, no apparent
defect on A3G was detected from CEM-T4 cells.
Since the antiretroviral activity of A3G is associated with its
presence in virions, we decided to further determine whether A3G
could be packaged into HIV-1 virions from CEM-T4 cells. To
produce sufficient amounts of virions, cell lines stably producing
HIV-1 virions were generated. HIV-1 viruses carrying a
neomycin-resistant gene were initially produced from 293T cells
after transfection with pNL-Neo or pNL-NeoDVif. A3.01, H9,
CEM-SS, and CEM-T4 cells were then infected with these viruses,
and stably infected cell lines were created by G418 selection.
Virions were then purified by ultra-centrifugation, and viral
Author Summary
Cytidine deaminases are host enzymes that remove the
amino group from the cytidine base on single-stranded
DNA or RNA, resulting in a replacement of the cytidine
with a uracil. Such replacement may alter the amino acid–
coding sequence of the gene and change protein function.
It has been well documented that APOBEC1 and AID play
very important roles in protein metabolism and immune
response via this mechanism. Interestingly, recent advanc-
es in retroviral researches have discovered that the seven
cytidine deaminases (APOBEC3A to 3H) on human
Chromosome 22 can restrict retrovirus replication. In
particular, APOBEC3G and APOBEC3F have the most
powerful anti–HIV-1 activity and also inhibit other retro-
viruses, including retrotransposons. They could inhibit viral
replication in either a cytidine deamination-dependent or -
independent manner, but the precise mechanism remains
to be defined. In this report, we found that in a particular
human T cell line, APOBEC3G and APOBEC3F failed to
block HIV-1 replication. Further analyses indicated that this
cell line lacks a cellular factor, which is very critical for
APOBEC3G and APOBEC3F antiviral activity. Thus, APO-
BEC3G and APOBEC3F require a cofactor to inhibit viral
replication, and identification of this cofactor will provide
an important strategy to decipher this poorly defined
antiretroviral mechanism.
A Cofactor for APOBEC3G/APOBEC3F
PLoS Pathogens | www.plospathogens.org 2 July 2008 | Volume 4 | Issue 7 | e1000095Figure 1. Productive replication of HIV-1DVif in CEM-T4 cells. (A) Cell surface expression of HIV-1 receptors. HUT 78, H9, PM1, CEM-SS, CEM-
T4, and A3.01 cells were stained with FITC-conjugated anti-CD4 and PE-conjugated anti-CXCR4 antibodies (BD Biosciences). Expression of these
surface molecules was determined by flow cytometry. (B) HIV-1 replication. Wild-type or vif-defective HIV-1 was produced from 293T cells after
transfection with pNL4-3 or pNL4-3DVif. HUT 78, H9, PM1, CEM-SS, CEM-T4, and A3.01 cells were then infected with these viruses, and viral
production was monitored daily using a p24
Gag ELISA for 8 d. Results shown are from 1 of 3 independent experiments. (C) A3G and A3F expression.
Cell lysates were prepared from indicated human T cell lines, and the expression of A3G or A3F was determined by Western blotting.
doi:10.1371/journal.ppat.1000095.g001
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were able to produce viruses as evidenced by the detection of
p24
Gag; Vif was only detectable in samples of the wild-type virus
but not the vif-deficient virus (Figure 2C). A3G was consistently
detected in virions from H9, A3.01, and CEM-T4 cells, but not
CEM-SS cells, and more A3G proteins were found in the vif-
defective than the wild-type virions. The level of A3G encapsida-
tion from CEM-T4 cells was lower than that from H9, but was at
least comparable to those from A3.01 cells (Figure 2C; compare
lanes 2, 4, 6). Thus, A3G was effectively encapsidated by HIV-1
from CEM-T4 cells. We further compared the infectivity of viruses
from CEM-SS, A3.01, and CEM-T4. We found that HIV-1DVif
infectivity was significantly reduced only in A3.01 cells, not CEM-
SS and CEM-T4 cells (Figure 2D). This result indicated that the
vif-deficient virions produced from CEM-T4 cells were still
infectious, which explained why CEM-T4 cells were permissive
for HIV-1DVif replication.
Trans-Complementation of CEM-T4 with Other Cellular
Factors
We developed two hypotheses to explain why CEM-T4 cells
are permissive for HIV-1DVif replication: 1) CEM-T4 cells lack
a cofactor essential for A3G/A3F anti-HIV activity; and 2)
CEM-T4 cells express a dominant inhibitor that blocks A3G/
A3F activity. A previously described trans-complementation assay
was used to test these hypotheses [52,53]. In this assay, CEM-T4
cells were fused with 293T cells to form heterokaryons. Because
293T can support A3G/A3F antiviral activity, if A3G/A3F
antiviral activity is restored in heterokaryons, it would indicate
that a cofactor is missing in CEM-T4 cells; otherwise, CEM-T4
cells should express an inhibitor. To ensure that infectious virions
are produced exclusively from heterokaryons, we expressed env-
deficient viral particles (HIV-1DEnv) in CEM-T4 cells and HIV-
1 Env protein in 293T cells. No infectious particle could be
produced from these two cell lines unless they formed
Figure 2. Characterization of A3G in CEM-T4 cells. (A) Isolation of A3G protein complexes. Cytosolic fractions were prepared from CEM-T4,
A3.01, and 293T cells transfected with human A3G expression vector. These lysates were treated or untreated with RNase A and then loaded on the
top of a 4% to 40% sucrose gradient. After centrifugation at 200,000g for 4 h, 9 fractions were collected, and A3G expression was determined by
Western blotting. (B) A3G deaminase activity. Cell lysates were prepared from indicated cell lines with or without RNase A treatment and then
subjected to scintillation proximity-based cytidine deaminase assay. Error bars represent standard deviations in 3 independent experiments. (C)
Production of HIV-1 from human T cell lines. H9, A3.01, CEM-SS, and CEM-T4 cells were infected with wild-type or vif-defective HIV-1 carrying a
neomycin-resistant gene, and stable cell lines were generated by G418 selection. Viruses were then collected from these cultures, and virion-
associated proteins were determined by Western blotting. (D) Viral infectivity assay. Viruses produced from the stable cell lines were collected and
used to infect TZM-bI cells. Viral infectivity was determined and normalized to viral input and expressed as relative values to the wild-type virus
infectivity from CEM-SS cells. The values for wild-type and vif-deficient virus infectivity are 100 and 90 from CEM-SS, 105 and 23 from A3.01 cells, and
72 and 89 from CEM-T4 cells. Error bars represent standard deviations in 3 independent experiments.
doi:10.1371/journal.ppat.1000095.g002
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fusion and trans-complemented for the missing viral components
(Figure 3A). The infectious viral particles were then detected by
infecting the HIV-reporter cell line TZM-bI, which contains an
integrated firefly luciferase gene under the control of the HIV
LTR.
Initial control experiments were performed with T cells that
support A3G/A3F anti–HIV-1 activity. A2.01, a CEM-derived
human T cell line that does not express CD4, was used as a
negative control, whereas A3.01, HUT 78, and H9 were used as
positive controls. Since A2.01 cells should not fuse to 293T cells,
no infectious particles should be recovered. Indeed, very low
luciferase activity was detected from TZM-bI cells inoculated with
culture supernatant from A2.01 and 293T coculture (Figure 3B;
lane 1). In sharp contrast, when A2.01 was replaced by A3.01,
HUT 78, or H9, 10- to 30-fold higher luciferase activities were
detected from TZM-bI, indicating a high efficiency of heterokary-
on formation and release of infectious particles from these
heterokaryons (Figure 3B; lanes 2–4).
Since CEM-SS cells do not express A3G/A3F, they were
further used to test the sensitivity of this system to A3G/A3F and
Vif activities. When A3G or A3F was not expressed in 293T cells,
infectious particles were recovered from heterokaryons regardless
of whether Vif was expressed (Figure 3B; lanes 5 and 8). However,
when A3G or A3F was expressed, infectious particles were only
recovered from heterokaryons in the presence of Vif (Figure 3B;
lanes 6 and 7), not in the absence of Vif (Figure 3B; lanes 9 and
10). These results not only demonstrated the efficiency and
accuracy of this trans-complementation assay, but also confirmed
the expression of corresponding proteins from different constructs.
Finally, we fused CEM-T4 cells with 293T cells. When Vif was
expressed in heterokaryons, infectious particles were recovered
regardless of whether A3G or A3F was expressed (Figure 3B; lanes
11–13). In sharp contrast, when Vif was not expressed and A3G or
A3F was expressed either from CEM-T4 or 293T, no infectious
particles were recovered (Figure 3B; lanes 14–16). These results
indicated that A3G/A3F in the heterokaryon between CEM-T4
and 293T could block HIV-1 replication. Thus, we concluded that
Figure 3. CEM-T4 cells lack an A3G/A3F cofactor. (A) A schematic description for transient trans-complementation assay. T cells were infected
with env-defective HIV-1 virus pseudotyped with VSV-G, and 293T cells were transfected with the Env-expressing vector pNLDGag. These two types of
cells were cocultured for heterokaryon formation. Infectious particles were then detected by infection of TZM-bI cells. (B) Infectivity of HIV-1
produced from heterokaryons. 293T cells were transfected with either pNLDGag or pNLDGagDVif in the presence or absence of a human A3G or A3F
expression vector and then cocultured with A2.01, A3.01, HUT 78, H9, CEM-SS, or CEM-T4 T cells that were infected with VSV-G–pseudotyped env-
defective HIV-1 expressing or not expressing Vif protein. Infectious particles were collected 48 h later and used to infect TZM-bI cells. Viral infectivity
was finally determined by measuring firefly luciferase activity in TZM-bI cell lysates. Results shown here were from 1 of 3 independent experiments.
doi:10.1371/journal.ppat.1000095.g003
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HIV activities.
HIV-1 Replication in CEM-T4 Cells Transiently Expressing
Exogenous A3G/A3F
Although we found that the endogenously expressed A3G/A3F in
CEM-T4 cells lost anti-HIV activity, we wanted to know whether
this defect is still present when these proteins are overly expressed.
We therefore attempted to express A3G or A3F genes transiently in
an HIV-based vector. A3F, A3G, or the noncatalytic A3G
(A3GE259Q) gene with a 39 HA tag was inserted into the Nef open
reading frame in either pNL4-3 or pNL4-3DVif vector so that these
A3proteinscould beexpressed during HIV-1 replication (Figure 4A;
top panel). In total, six different HIV-1 proviral constructs were
generated: pNLA3F, pNLA3FDVif, pNLA3G, pNLA3GDVif,
pNLA3GE259Q, and pNLA3GE259QDVif.
To test their activities, recombinant viruses were first produced by
transfection of 293T cells and viral infectivity was determined. To
further confirm A3G/A3F gene function in these vectors, we
cotransfected the vif-defective version of these vectors with pNL-A1.
pNL-A1 isa Vif expression vectorcreated from pNL4-3 with mostof
the viral genes deleted, including the viral RNA packaging signal,
and can only provide Vif expression in trans for a single round. High
levelsof A3G orA3GE259Q expression weredetected intransfected
293T cells in the absence of Vif by Western blotting (Figure 4A;
middle panels; lanes 5 and 8), and their expressions were decreased
by Vif expressed either in cis or in trans (Figure 4A; lanes 4, 6, 7, 9).
The expression of A3F was relatively low (Figure 4A; lane 2), and Vif
further decreased this expression (Figure 4A; lanes 1 and 3). Next,
recombinant viruses were collected to infect TZM-bI cells for a
single-round replication. Overall, these viruses had a very similar
infectivity in the presence of Vif (Figure 4A; bottom panel; lanes 1, 3,
4, 6, 7, 9). However, A3 proteins decreased viral infectivity when Vif
was absent. The wild-type A3G had the most powerful anti-HIV
activity,whichreducedviralinfectivitybyaround10-fold(Figure4A;
lane 5). Both A3F and A3GE259Q mutant reduced viral infectivity
by around 2-fold (Figure 4A; lanes 2 and 8). The low anti-HIV
activity of A3F could be due to its low expression, and the low
activity of A3GE259Q is consistent with previous reports [16,54–
56]. Nevertheless, this result confirmed that these constructs
expressed functional A3G or A3F proteins.
Next, we infected CEM-SS and CEM-T4 cells with these
recombinant HIV viruses. In this experiment, pNLA3 indicates
HIV-1 expressing both Vif and A3 proteins, pNLA3DVif indicates
viruses expressing only A3 protein, and pNLA3DVif+Vif indicates
viruses expressing Vif provided in trans by pNL-A1 and A3 proteins.
As presented in Figure 4B, the replication of both pNLA3FDVif and
pNLA3FDVif+Vif were slightly delayed in CEM-SS cells when
compared with pNLA3F, and this result was reversed in CEM-T4
cells; the replication of both pNLA3GE259QDVif and pNLA3-
Figure 4. Anti-HIV activity of A3F/A3G proteins expressed in cis from an HIV-based vector. (A) Expression of A3G/A3F from an HIV-based
vector and the antiviral infectivity in a single round replication assay. An A3F, A3G, or A3GE259Q gene with an HA tag was inserted into the Nef open
reading frame in pNL4-3 or pNL4-3DVif. These constructs were then cotransfected into 293T cells with either pNL-A1 or its control pNL-A1DVif as
indicated. Expressions of Vif and A3 proteins in these transfections were determined by Western blotting, and viral infectivity was determined in TZM-
bI cells. (B) Replication kinetics of HIV-1 viruses expressing A3G or A3F. CEM-SS and CEM-T4 cells were infected with the same amount of A3G- or A3F-
expressing HIV-1 viruses used as in (A); viral growth curves were determined by measuring p24
Gag in the supernatants. pNLA3FDVif + Vif, pNLA3GDVif
+ Vif, and pNLA3GE259QDVif + Vif are viruses produced in the presence of pNL-A1 during transfection of 293T cells.
doi:10.1371/journal.ppat.1000095.g004
A Cofactor for APOBEC3G/APOBEC3F
PLoS Pathogens | www.plospathogens.org 6 July 2008 | Volume 4 | Issue 7 | e1000095GE259QDVif+VifwerealsoslightlydelayedinCEM-SScellsduring
the first 3 d of infection, and all three A3GE259Q-expressing viruses
replicated equally well in CEM-T4 cells; the replication of
pNLA3GDVif and pNLA3GDVif+Vif but not pNLA3G viruses
was strictly restricted in CEM-SS cells, and all 3 viruses replicated
almost equally well in CEM-T4 cells. The growth curve of these
viruses in CEM-SS cells was consistent with their infectivity data in
Figure 4A, confirming that A3F only weakly inhibited viral
replication due to low expression, A3G potently inhibited viral
replication, and A3GE259Q had very low antiviral activity.
Nonetheless, since all vif-deficient viruses expressing A3G or A3F
replicated very well in CEM-T4 cells, these results indicated that
A3G/A3F lost their antiviral activity, which further supported that
CEM-T4 cells lack a cofactor. The slight delay of pNLA3GDVif
virus replication in CEM-T4 cells could be due to an incorporation
of this cofactor from 293T cells that compensated A3G activity
during the first round of infection, which provides another piece of
evidence that CEM-T4 cells do not express this cofactor.
HIV-1 Replication in CEM-T4 Cells Stably Expressing
Exogenous A3G/A3F
To further confirm these observations, we stably transduced
CEM-T4 or CEM-SS cells with an A3G, A3GE259Q, A3F, or
GFP gene by the murine leukemia virus (MuLV)-based vector
pMSCVneo. These genes, containing a 39 HA-tag, were inserted
into pMSCVneo, and recombinant MuLV viruses were created by
transfection of Phoenix-AMPHO cell line. Viruses were then used
to infect CEM-T4 or CEM-SS cells, and 8 stable cell lines were
created by G418 selection. All transduced genes were expressed
although the expression of A3F and GFP was lower than that of
A3G and A3GE259Q (Figure 5A). It is known that human A3G
inhibits MuLV replication, but one group reported that this
inhibition might not depend on cytidine deamination [57].
Nevertheless, we wanted to make sure that the tranduced gene
did not contain any mutation. The exogenous A3G and A3F genes
in CEM-T4 cells were cloned and sequenced, and no mutation
was found (unpublished data). Thus, these cell lines should express
functional exogenous A3G/A3F proteins.
Another possibility that A3G/A3F lost anti-HIV activity is that
they are mislocalized in CEM-T4 cells. To exclude this possibility,
we compared A3G subcellular localization in CEM-T4 and CEM-
SS cells by confocal microscopy. A3G and A3F are both known as
cytoplasmic proteins, and can be found in the mRNA processing
(P) bodies [58,59]. A recent report showed that A3F is colocalized
with cellular protein MOV10 [48], which is also a P-body protein
[60]. When stable CEM-T4 and CEM-SS cells expressing A3G
were stained with anti-A3G and anti-MOV10 antibodies, A3G
protein was found in the cytoplasm of both cell lines and was
colocalized with MOV10 (Figure 5B). Thus, A3G/A3F should not
be mislocalized in CEM-T4 cells.
Finally, we determined HIV-1 replication in these cell lines. As
presented in Figure 5C, both wild-type and vif-deficient HIV-1
replicated equally well in CEM-T4 cells expressing A3G,
A3GE259Q, A3F, or GFP, suggesting that the vif-deficient virus
is not restricted by any of these genes. However, in CEM-SS cells,
although the replication of vif-deficient virus was not restricted by
GFP or A3GE259Q, it was severely restricted by A3G or A3F.
The anti-HIV activity of A3F in CEM-SS cells was relatively lower
than that of A3G, which could be due to its low expression as
shown in Figure 5A. In addition, the poor activity of A3GE259Q
further confirmed that this noncatalytic A3G mutant has poor
antiviral activity. Thus, we concluded that A3G/A3F failed to
inhibit HIV-1 replication in CEM-T4 cells even though they were
overexpressed.
Discussion
In this report, we studied A3G/A3F anti–HIV-1 activity in 6
different human T cell lines. We found that in one cell line, CEM-
T4, A3G/A3F lost anti–HIV-1 activity due to the absence of a
cellular factor, which is very critical for A3G/A3F anti-HIV activity.
Although A3G/A3F potently inhibits HIV-1 replication, this
mechanism isstill poorlydefined. A3G/A3Fhastwo conserved zinc-
binding domains. In the process of blocking HIV-1 replication, these
two domains have different functions. The N-terminal domain has a
high affinity for RNAs, which normally serves as a virion-packaging
signal, and the C-terminal domainhas cytidine deamination activity,
which isthe real catalyticdomain[61–63].Initially,itwasfound that
the noncatalytic A3G mutant E259Q still retained intact anti-HIV
activity, suggesting that the cytidine deaminase activity is not
required for antiviral activity [64]. However, this result could not be
reproduced by the other investigators [16,54–56], and we also found
that the E259Q mutant had very marginal anti-HIV activity
(Figures 4B and 5C). Nevertheless, it is clear that A3G could inhibit
the replication of hepatitis B virus and human T cell leukemia virus
type 1 in the absence of cytidine deamination [36,37], and many
similar cases have been found in blocking HIV-1, adeno-associated
virus, and retrotransposon replications by different A3 proteins
[5,14,15,18,32–35]. Thus, although cytidine deamination is not
required, the cytidine deaminase activity is absolutely required for
A3 antiretroviral activities.
As introduced before, A3G/A3F can reduce the accumulation of
HIV-1 cDNAs, which correlates well with their anti-HIV activity.
Previously, two groups reported that uracil DNA glycosylases-2
(UNG), a host DNA repair enzyme, is involved in the degradation of
viral cDNAs containing uracils [65,66]. However, another two
groups obtained conflicting results and dismissed the role of this
enzyme in A3G antiviral activity [16,67]. In addition, A3G/A3F
were shown to inhibit tRNA
lys3 priming, elongation, or DNA strand
transfer during reverse transcription and viral integration [38–44].
How A3G/A3G can virtually disrupt these critical reactions in the
viral life cycle needs to be understood. Notably, the presence of an
A3G/A3F antiretroviral cofactor may help decipher this poorly
defined mechanism. One possibility is that this cofactor has nuclease
activity that directly degrades viral reverse transcripts. Alternatively,
it may increase the affinity of A3G/A3F to viral RNAs or cDNAs so
that they can compete with viral reverse transcriptase and integrase
for their substrates. Although it was expected that A3G/A3F would
specifically interact with viral RNAs or cDNAs to block HIV-1
replication, in vitro study with recombinant A3G proteins failed to
demonstrate such specificity [68,69]. In the case of another
deaminase, A1, it has been shown that its editing activity is a highly
sequence-specific process dependent upon the primary, secondary,
and perhaps even tertiary structure of the RNA substrate. Further
investigations have identified two host factors that are required to
complement A1 for apoB mRNA editing: ACF (APOBEC1
complementation factor) and its splice variant ASP (APOBEC1
stimulating protein) [70,71]. ACF is very homologous to the RNA-
binding protein GRY-RBP and binds to the U-rich ‘‘mooring’’
sequence of apoB mRNA [71]. Thus, similar cofactors may also be
required for A3G/A3F.
Two groups have reported that human A3G/A3F could inhibit
yeast LTR retrotransposon Ty1 in Saccharomyces cerevisiae [12,17].
Whether a similar cofactor is required for A3G/A3F antiretroviral
activity in yeast therefore becomes an interesting question. If it is
required, it would imply that a highly conserved antiviral ortholog
gene exists in different organisms. Otherwise, it may indicate that
this cofactor is very specific for HIV-1. The latter possibility could
also suggest that A3G/A3F uses different antiviral mechanisms to
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cofactor involved in the process of blocking HIV-1 replication
by A3G/A3F is critical to our understanding of HIV pathogenesis.
Further characterization of this cofactor will lead to a complete
understanding of A3G/A3F anti-HIV activity.
Materials and Methods
Plasmids, Cell Lines, and Viruses
HIV-1 proviral constructs pNL4-3 and pNL4-3DVif and
human A3G or A3F expression pcDNA3.1-V5-6XHis vectors
have been described previously [6,11]. The noncatalytic A3G
mutant (A3GE259Q) was created by site-directed mutagenesis
in pcDNA3.1 vector. pNL-Neo, pNL-NeoDVif, pNLA3G,
pNLA3GDVif, pNLA3F, pNLA3FDVif, pNLA3GE259Q, and
pNLA3GE259QDVif were created by replacing the firefly
luciferase gene in pNL-Luc and pNL-LucDVif with a neomycin-
resistant gene or an A3G, A3F, or A3GE259Q gene containing a
39 HA-tag by NotI/XhoI digestion, respectively. In addition, an
A3F, A3G, A3GE259Q, or GFP gene with a 39 HA tag was
inserted into the pMSCVneo vector by EcoRI/XhoI digestion.
pNL4-3DGag and pNL4-3DEnv were created by SphI/AgeI
Figure 5. Anti-HIV activity of A3F/A3G proteins expressed in trans from a MuLV-based vector. (A) Stable transduction of CEM-T4 and
CEM-SS cells by MuLV-based vector. An A3F, A3G, A3GE259Q, or GFP gene with an HA tag was inserted into the pMSCVneo vector, and recombinant
MuLV was produced. CEM-T4 and CEM-SS cells were then infected with these viruses, and stably infected cells were selected by G418 treatment. The
expression of A3F/A3G proteins in each individual cell line was determined by Western blotting. (B) A3G subcellular localization. CEM-T4 and CEM-SS
cells stably transduced with A3G were fixed with formaldehyde and then stained with a mouse anti-A3G monoclonal antibody and a rabbit anti-
MOV10 polyclonal antibody. A3G was visualized using Alexa Fluor 488–conjugated secondary antibody (green), and MOV10 was visualized by Alexa
Fluor 594–conjugated antibody (red). The cells were also stained with Hoechst 33342 to visualize nuclei (blue). Areas of overlap between A3G and
MOV10 appear as yellow. (C) Replication kinetics of HIV-1 in stably transduced cell lines. CEM-T4 and CEM-SS cells stably transduced with A3G,
A3GE259Q, A3F, or GFP were infected with the same amount of wild-type or vif-deficient HIV-1. Viral growth curves were determined by measuring
p24
Gag in the supernatants using ELISA.
doi:10.1371/journal.ppat.1000095.g005
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large Klenow fragment treatment before T4 ligation. The NheI
site is still active in pNL4-3DEnv although the env gene was
inactivated by frame-shift. To create pNL4-3DGagDVif and
pNL4-3DEnvDVif, the parental plasmids were digested with
PfiMI and filled in with a linker from annealing two DNA
oligonucleotides (59-CTAGCTAGCTAGCCGGCAGA-39,5 9-
GCCGGCTAGCTAGCTAGTCT-39).
The HIV indicator cell line TZM-bI and human T cell lines
HUT 78, H9, PM1, CEM-SS, CEM-T4, A3.01, and A2.01 were
from the National Institutes of Health (NIH) AIDS Research and
Reference Reagent Program. The Phoenix-AMPHO cell line was
from Dr. G. Nolan (Stanford University). T cell lines were cultured
in RPMI 1640 with 10% fetal bovine serum (HyClone). Phoenix-
AMPHO, 293T, and TZM-bI were cultured in DMEM with 10%
bovine calf serum (HyClone).
HIV-1 or MuLV viruses were produced from 293T or Phoenix-
AMPHO cells by the standard calcium phosphate transfection.
HIV-1 Infection of Human T Cell Lines
A total of 1610
5 cells were incubated with 100 ng wild-type or
Vif-defective HIV viruses at 37uC for 3 h. After removal of the
inocula, followed by 3 extensive washings, cells were cultured in
24-well plates for 8 d. Culture supernatants were then collected
daily for measurement of p24
Gag by ELISA.
Cytidine Deaminase Assay
A scintillation proximity-based assay was used as described
previously [46,72].
Western Blotting
The rabbit anti-human A3G polyclonal antibody was from the
NIH AIDS Research and Reference Reagent Program. The
mouse anti-human A3F polyclonal antibody was from Abnova,
Taiwan. Actin was detected by a polyclonal antibody (C-11; Santa
Cruz Biotechnology). HIV-1 p24
Gag and Vif were detected by
antibodies (nos. 3537 and 6459) from the NIH AIDS Research
and Reference Reagent Program. HRP-conjugated anti-rabbit or
mouse IgG secondary antibodies were from PIERCE. Detection of
the HRP-conjugated antibody was performed using Supersignal
Wetpico Chemiluminescence Substrate kit (PIERCE).
Heterokaryon Formation
A previously established protocol was adopted [52,53]. Briefly,
293T cells were seeded in 6-well plates at 8610
5/well in 2 ml
medium. After 12 h, cells were transfected with 6 mg of HIV Env
expression vector pNL4-3DGag or pNL4-3DGagDVif in the
presence or absence of A3G or A3F expression vector and washed
with PBS 4 h later. Simultaneously,8610
5 T cells were infected with
500 ng of VSV-pseudotyped Env-defective HIV-1 from pNL4-
3DEnv– or pNL4-3DEnvDVif–transfected 293T cells at 37uCf o r
3 h. After removal of the inocula and extensive washing, infected T
cells were added to the Env-expressing 293T cell culture. After 48 h,
supernatants from these cocultures were collected to infect TZM-bI
cells. Viral infectivity was finally determined by measuring cellular
luciferase activities after another 48 h.
Immunocytochemistry
CEM-T4 cells stably expressing exogenous A3G from the
pMSCVneo vector were fixed in a buffer (5% formaldehyde+2%
sucrose in PBS). Fixed samples were permeabilized for 30 min at
room temperature in a permeabilization buffer (1% Triton X-100,
10% sucrose in PBS) prior to incubation with antibodies. Cells
were then stained with a mouse anti-A3G monoclonal antibody at
1:100 (ImmunoDiagnostics, obtained from the NIH AIDS
Research and Reference Reagent Program) and a rabbit anti-
MOV10 polyclonal antibody at 1:100 (Proteintech Group). Cover
slips were washed once in PBS (5 min at room temperature) and
incubated with secondary antibodies, including goat anti-mouse
IgG Alexa Fluor 488 and goat anti-rabbit IgG Alexa Fluor 594
(Invitrogen). Cells were further stained with 1 mg/ml Hoechst
33342 (Sigma-Aldrich, St. Louis, Missouri, United States of
America). Cover slips were then washed twice with PBS and
mounted onto microscope slides with glycerol gelatin (Sigma-
Aldrich) and were stored at 4uC in the dark until analyzed by a
confocal microscope Olympus Fluoview 1000.
Accession Numbers
The GenBank accession numbers for human APOBEC3G and
APOBEC3F are BC024268 and BC038808.
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